Pluri Inc
PLUR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.42M
Close$
$-2.91
334.6% downside
Current Fair Value
334.6% downsideOvervalued by 334.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $13.42 Million |
|---|---|
| Enterprise Value | $17.44 Million |
| Earnings per Share | $-2.44 |
| Beta | 0.69 |
| Outstanding Shares | 10,824,311 |
Return
| Return on Equity | 108.77% |
|---|---|
| Return on Assets | -155.16% |
| Return on Invested Capital | 152.28% |
Valuation & Multiples
| P/E Ratio | -0.51 |
|---|---|
| PEG | 2.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 17.17 |
| Enterprise Value to EBIT | -0.69 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | -0.33 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
$-0.66
Consensus analyst estimateRevenue Estimate
$655,000
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 0.00% |
|---|---|
| Total Invested | $55,311▼ 39.43% |
| Investors Holding | 16▲ 3.00% |
About Pluri Inc
152 employees
CEO: Zalman Aberman
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell...